At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 127 enrolled
Drug / intervention
BG505 SOSIP.664 gp140 +6 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Aalum Adjuvants and VRC HIV Env Trimer 4571 and 3M-052-AF With Alum in Healthy, HIV-uninfected Adults
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Nov 26, 2019·Updated Sep 2, 2025
In Brief
A Phase 1 clinical trial evaluating BG505 SOSIP.664 gp140, Placebo, and 5 other interventions for HIV Infections. Completed, enrolled 127 participants across 10 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 BG505 SOSIP.664 gp140 with TLR agonist and/or alum adjuvants in healthy, HIV-uninfected adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartJan 2020
Primary CompletionNov 2024
TodayJul 2026
First PostedNov 26, 2019
Enrollment StartJan 13, 2020
Primary CompletionNov 4, 2024
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 6.6 years ago
Interventions
BG505 SOSIP.664 gp140biological
Administered by IM injection
Placebobiological
Administered by IM injection
3M-052-AFbiological
Administered by IM injection
CpG 1018biological
Administered by IM injection
GLA-LSQbiological
Administered by IM injection
Alum (Aluminum Hydroxide Suspension)biological
Administered by IM injection
Trimer 4571biological
Administered by IM injection